- Home
- TNL vs ACAD Comparison
TNL vs ACAD Comparison
Compare TNL & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNL
- ACAD
- Stock Information
- Founded
- TNL 1990
- ACAD 1993
- Country
- TNL United States
- ACAD United States
- Employees
- TNL N/A
- ACAD N/A
- Industry
- TNL Hotels/Resorts
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- TNL Consumer Discretionary
- ACAD Health Care
- Exchange
- TNL Nasdaq
- ACAD Nasdaq
- Market Cap
- TNL 3.3B
- ACAD 3.5B
- IPO Year
- TNL N/A
- ACAD 2004
- Fundamental
- Price
- TNL $58.40
- ACAD $23.53
- Analyst Decision
- TNL Buy
- ACAD Buy
- Analyst Count
- TNL 11
- ACAD 18
- Target Price
- TNL $62.27
- ACAD $27.94
- AVG Volume (30 Days)
- TNL 817.2K
- ACAD 1.7M
- Earning Date
- TNL 07-23-2025
- ACAD 08-06-2025
- Dividend Yield
- TNL 3.86%
- ACAD N/A
- EPS Growth
- TNL N/A
- ACAD N/A
- EPS
- TNL 5.78
- ACAD 1.37
- Revenue
- TNL $3,915,000,000.00
- ACAD $996,283,000.00
- Revenue This Year
- TNL $4.19
- ACAD $13.28
- Revenue Next Year
- TNL $3.87
- ACAD $10.88
- P/E Ratio
- TNL $10.03
- ACAD $17.41
- Revenue Growth
- TNL 2.46
- ACAD 22.42
- 52 Week Low
- TNL $37.77
- ACAD $13.40
- 52 Week High
- TNL $63.31
- ACAD $25.23
- Technical
- Relative Strength Index (RSI)
- TNL 53.88
- ACAD 61.47
- Support Level
- TNL $61.54
- ACAD $22.40
- Resistance Level
- TNL $63.31
- ACAD $24.06
- Average True Range (ATR)
- TNL 1.59
- ACAD 0.72
- MACD
- TNL -0.24
- ACAD 0.09
- Stochastic Oscillator
- TNL 33.56
- ACAD 76.96
About TNL Travel Leisure Co. Common Stock
Travel+Leisure Co is a membership and leisure travel company. It provides hospitality services and travel products. The company operates in the segments of Vacation Ownership, which is the key revenue-driving segment, develops, markets and sells vacation ownership interests (VOIs) to individual consumers, provides consumer financing in connection with the sale of VOIs, and provides property management services at resorts, and Travel and Membership which operates a variety of travel businesses, including three vacation exchange brands, a home exchange network, travel technology platforms, travel memberships, and direct-to-consumer rentals. The majority of the revenue is earned from the United States.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.